OM
KROS icon

Opaleye Management’s Keros Therapeutics KROS Stock Holding History

Opaleye Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-395,276
Closed -$23M – 45
2024
Q3 		$23M Buy
395,276
+27,776
+8% +$1.37M 3.83% 7
2024
Q2 		$16.8M Hold
367,500
– – 3.84% 5
2024
Q1 		$24.3M Buy
367,500
+10,000
+3% +$593K 5.3% 4
2023
Q4 		$14.2M Sell
357,500
-2,900
-0.8% -$90.9K 3.78% 7
2023
Q3 		$11.5M Buy
360,400
+7,750
+2% +$289K 3.74% 7
2023
Q2 		$14.2M Buy
352,650
+114,650
+48% +$5.03M 3.39% 6
2023
Q1 		$10.2M Hold
238,000
– – 3.04% 7
2022
Q4 		$11.4M Sell
238,000
-83,300
-26% -$3.89M 3.97% 7
2022
Q3 		$12.1M Buy
321,300
+45,300
+16% +$1.57M 4.99% 7
2022
Q2 		$7.63M Buy
276,000
+10,250
+4% +$450K 3.44% 11
2022
Q1 		$14.5M Hold
265,750
– – 4.49% 7
2021
Q4 		$15.5M Sell
265,750
-86,750
-25% -$4.33M 3.3% 11
2021
Q3 		$13.9M Buy
352,500
+117,500
+50% +$4.18M 2.6% 12
2021
Q2 		$9.98M Buy
235,000
+77,500
+49% +$4.2M 1.66% 19
2021
Q1 		$9.69M Buy
+157,500
New +$9.98M 1.42% 20

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Opaleye Management's KROS Position: Q4 2024 in Review

Opaleye Management sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 395,276 shares — an estimated $23M sold.

Opaleye Management first reported a position in KROS in Q1 2021 and held it in 15 quarters. The position peaked at $24.3M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Opaleye Management reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Opaleye Management sold 395,276 Keros Therapeutics shares in Q4 2024, an estimated $23M.
  • Opaleye Management first reported a position in Keros Therapeutics in Q1 2021 and held it in 15 quarters.
  • Opaleye Management's Keros Therapeutics position peaked at $24.3M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.